ClinicalTrialsFinder
RecruitingPhase 3NCT04821778

Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer

Cohort Study of Definitive Chemoradiotherapy for Esophageal or Esophagogastric Junction Cancer

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Enrollment

2,000 participants

Start Date

Jan 1, 2002

Study Type

INTERVENTIONAL

Conditions

Esophagus CancerChemotherapy EffectTargeted TherapyImmunotherapyChemoradiationEsophagogastric Junction Cancer

Summary

Definitive chemoradiotherapy is the standard of care in unresectable esophageal or esophagogastric cancer. A multidisciplinary approach, including chemotherapy and radiotherapy, is important for these patients. Morerover, molecular targeting agents does not show clear efficacy in EC up to now. Nowadays, the pace of development of cancer immunotherapies is accelerating. Clinical evidence of the efficacy of immune checkpoint inhibitors and adoptive immunotherapies herald the onset of a new era in cancer immunotherapy. There have also been recent developments to provide a promising frontier in extending the use of immunotherpay or targeting agents to radiotherapy. The purpose of this study was to explore the optimal treatment modalities including PD-1/PD-L1 antibody or targeted drug for patients with unresectable esophageal or esophagogastric junction cancer.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This trial studies the real-world safety and effectiveness of chemoradiotherapy for patients with esophageal or esophagogastric junction cancer. **You may be eligible if...** - You are 18 or older with esophageal or esophagogastric cancer - Your cancer is confirmed by biopsy (squamous cell or adenocarcinoma, stages I–IVa) - You are being treated at the Cancer Hospital, Chinese Academy of Medical Sciences - Your performance status and organ function meet protocol requirements **You may NOT be eligible if...** - Your cancer has spread to distant organs (liver, lungs, bone, brain) - You have had another cancer in the last 5 years (except certain skin or cervical cancers) - You have active infections such as tuberculosis or hepatitis - You had a heart attack in the last 6 months or have serious heart rhythm problems Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

RADIATIONRadiotherapy

50-66Gy/1.8-2.2Gy/25-30f

DRUGPlatinum based chemotherapy

q1-3W according to physician's preference

DRUGPaclitaxel based chemotherapy

q1-3W according to physician's preference

DRUGImmunotherapy

Anti-PD-1/PD-L1 Antibody

DRUG5-FU Analog based chemotherapy

W1-5 qW or d1-14, q3W according to physician's preference

DRUGNimotuzumab

200-400mg, d1,qW

Locations(5)

Department 4th of Radiation Oncology, Anyang Cancer Hospital

Anyang, Henan, China

Hunan Cancer Hospital, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University

Changsha, Hunan, China

Department of Radiation oncology, Jiangsu Cancer Hospital/Jiangsu Institute of Cancer Research/The affiliated Cancer Hospital of Nanjing Medical University

Nanjing, Jiangsu, China

Department of Radiation oncology, Jiangsu Province Hospital/The First Affiliated Hospital with Nanjing Medical University

Nanjing, Jiangsu, China

Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC)

Beijing, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04821778

Related Trials

Study of the Effectiveness and Safety of Daunorubicin /Idarubicin ± Silibinin in Treating Newly Diagnosed AML (Non-M3).

NCT075618921 location

Exploring Physical and Psychological Needs and Quality of Life in Patients With Advanced Cancer Receiving Immunotherapy

NCT064617801 location

IMMUNO-FIT Observational Study

NCT073549711 location

CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer

NCT051871821 location

A Pilot Study Evaluating β-hydroxybutyrate Supplementation Concomitant to Short-Course Radiotherapy Followed by Immunotherapy Combined With CAPEOX Neoadjuvant Therapy in Patients With Locally Advanced Rectal Cancer

NCT072394661 location